Financial Performance - The company's revenue for Q1 2025 was CNY 2,477,948,927.49, representing a 5.42% increase compared to CNY 2,350,478,362.11 in the same period last year[4] - Net profit attributable to shareholders was CNY 370,082,216.76, a 1.87% increase from CNY 363,297,720.56 year-on-year[4] - The net profit after deducting non-recurring gains and losses increased by 26.09% to CNY 378,502,314.92 from CNY 300,194,937.03 in the previous year[4] - Basic earnings per share for Q1 2025 was ¥0.45, up from ¥0.44 in Q1 2024[17] - The total comprehensive income for Q1 2025 was ¥363,235,743.84, slightly up from ¥362,987,690.02 in Q1 2024[16] Cash Flow - The net cash flow from operating activities improved to -CNY 353,474,219.65, compared to -CNY 657,050,656.93 in the same period last year[4] - Cash flow from operating activities in Q1 2025 was negative at -¥353,474,219.65, an improvement from -¥657,050,656.93 in Q1 2024[18] - The net cash flow from investment activities was $42,049,490.76, a significant improvement compared to a negative cash flow of -$1,123,792,938.39 in the previous period[19] - The net cash flow from financing activities was -$9,102,182.39, compared to -$52,965,585.80 in the previous period, indicating a reduced outflow[19] Assets and Liabilities - The total assets at the end of the reporting period were CNY 28,846,018,517.29, a 2.89% increase from CNY 28,035,688,872.48 at the end of the previous year[5] - The company's total liabilities increased to RMB 8,563,210,960.39 from RMB 8,129,447,799.81, which is an increase of about 5.3%[13] - The equity attributable to shareholders reached RMB 20,284,291,823.43, up from RMB 19,903,165,417.53, reflecting a growth of approximately 1.9%[13] - The company's current assets totaled RMB 21,178,583,764.62, compared to RMB 20,893,841,318.46 at the end of 2024, indicating an increase of about 1.37%[12] Research and Development - Research and development expenses totaled CNY 567,853,212.94, up 12.01% from CNY 506,949,927.30, accounting for 22.92% of total revenue[5] - Research and development expenses for Q1 2025 were ¥378,872,051.95, down 9.7% from ¥419,681,857.09 in Q1 2024[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,435[8] - The company received government subsidies amounting to CNY 17,600,465.75 during the period[6] Inventory and Receivables - The company's inventory increased to RMB 6,137,986,392.11 from RMB 5,528,382,408.16, indicating a rise of about 11%[11] - Accounts receivable rose to RMB 4,907,131,343.58 from RMB 4,358,808,221.15, marking an increase of around 12.6%[11] Cash and Cash Equivalents - The cash and cash equivalents decreased to RMB 7,185,525,069.64 from RMB 8,399,997,063.38, representing a decline of approximately 14.5%[11] - The cash and cash equivalents at the end of the period were $5,546,756,540.92, down from $5,867,855,094.11 at the beginning of the period[19] - The company’s cash and cash equivalents decreased by $321,098,553.19 during the period[19] Other Financial Metrics - The weighted average return on equity decreased slightly to 1.84% from 1.91%[5] - Operating profit for Q1 2025 was ¥398,763,564.24, compared to ¥400,407,296.57 in Q1 2024, indicating a decrease of 0.4%[16] - Total operating costs for Q1 2025 were ¥2,132,796,705.76, an increase of 3.8% from ¥2,055,132,564.46 in Q1 2024[15] - Other income for Q1 2025 was ¥115,812,587.45, compared to ¥105,262,737.48 in Q1 2024, reflecting an increase of 10.5%[15] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[19]

上海联影医疗科技股份有限公司 关于 2024 年度会计师事务所的履职情况评估报告 （三）上市公司与前后任会计师事务所的沟通情况 根据《国有企业、上市公司选聘会计师事务所管理办法》等相关规范性文件 的规定，上海联影医疗科技股份有限公司（以下简称"公司"）对安永华明会计 师事务所（特殊普通合伙）（以下简称"安永华明"）在 2024 年度的审计工作的 履职情况进行了评估。经评估，公司认为安永华明在资质等方面合规有效，履职 保持独立性，勤勉尽责，公允表达意见。具体情况如下： 一、会计师事务所的基本情况 安永华明于 1992 年 09 月成立，2012 年 08 月完成本土化转制，从一家中外 合作的有限责任制事务所转制为特殊普通合伙制事务所。安永华明总部设在北京， 注册地址为北京市东城区东长安街 1 号东方广场安永大楼 17 层 01-12 室。 安永华明的首席合伙人为毛鞍宁。截至 2023 年 12 月 31 日，安永华明合伙 人人数为 245 人，注册会计师人数为 1,800 人，其中签署过证券服务业务审计报 告的注册会计师近 500 人。 二、前任会计师事务所的情况 （一）前任会计师事务所情况及上年度审计意见 公 ...

上海联影医疗科技股份有限公司 2024 年度 募集资金存放与实际使用情况专项报告 及鉴证报告 目录 上海联影医疗科技股份有限公司董事会： 我们接受委托，对后附的上海联影医疗科技股份有限公司 2024 年度募集资金存放 与实际使用情况的专项报告（"募集资金专项报告"）进行了鉴证。按照《上市公司监 管指引第 2 号——上市公司募集资金管理和使用的监管要求》、《上海证券交易所科创 板上市公司自律监管指引第 1 号——规范运作》及相关格式指南编制募集资金专项报告， 并保证其内容真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏是上海联影 医疗科技股份有限公司董事会的责任。我们的责任是在执行鉴证工作的基础上对募集资 金专项报告独立发表鉴证意见。 页码 | 一、募集资金存放与实际使用情况鉴证报告 | 1 - 2 | | --- | --- | | 二、上海联影医疗科技股份有限公司 2024 年度募集资金 | | | 存放与实际使用情况专项报告 | 3 - 9 | | 三、附表：2024 年度募集资金使用情况对照表 | 10 | 募集资金存放与实际使用情况鉴证报告 安永华明（2025）专字第70030227_B02号 ...

一、审计委员会基本情况 公司第二届董事会审计委员会由独立董事王少飞先生、盛雷鸣先生及非独立 董事沈思宇先生 3 名成员组成，其中独立董事占比为三分之二，并由具备会计专 业资格和经验的王少飞先生担任审计委员会主任委员。审计委员会的成员资格和 构成均符合有关法律法规的规定。 二、审计委员会会议召开情况 报告期内，审计委员会共召开 6 次会议，具体情况如下： | 会议名称 | | | 召开日期 | 会议内容 | | --- | --- | --- | --- | --- | | | | | | 审计委员会经过充分沟通讨论，一致审议通过《关于公司 | | 第二届董事会审计 | | | | 2023 年年度报告及摘要的议案》《关于公司 2023 年内部控制 | | 委员会 | 2024 | 年第一 | 2024.4.25 | 评价报告的议案》《关于公司 2023 年度财务决算报告的议案》 | | 次会议 | | | | 《关于续聘 2024 年度会计师事务所的议案》《关于公司 2024 | | | | | | 年第一季度报告的议案》 | | 第二届董事会审计 | | | | 审计委员会经过充分沟通讨论，一致审议通过《关 ...

Introduction to the Report Sustainable Development Management 2024 Environmental, Social and Governance Report Shanghai United Imaging Healthcare Co., Ltd. 1 Accessible and Inclusive Healthcare 03 14 20 27 38 56 Cutting-Edge Technology Lean Products and Quality Service Equality, Diversity and Common Growth Assuming Responsibilities and Joining in Public Benefit Activities Clean Production for Green Development 78 81 90 102 Compliant Operation for Steady Development Appendix 102 Index of Guidelines on Self-d ...

经核查独立董事 JIA HONG GAO、王少飞、盛雷鸣及其直系亲属和主要社会 关系人员的任职经历以及独立董事签署的相关自查文件，独立董事 JIA HONG GAO、 王少飞、盛雷鸣不存在《上市公司独立董事管理办法》第六条不得担任独立董事 的情形，在担任公司独立董事期间，独立董事已严格遵守中国证监会和上海证券 交易所的相关规定，确保有足够的时间和精力勤勉尽责地履行职责，作出独立判 断，不受公司主要股东、实际控制人或其他与公司存在利害关系的单位或个人的 影响。公司独立董事 JIA HONG GAO、王少飞、盛雷鸣符合《上市公司独立董事 管理办法》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 中对独立董事独立性的相关要求。 上海联影医疗科技股份有限公司董事会 关于独立董事独立性情况的专项意见 根据《上市公司独立董事管理办法》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》等要求，上海联影医疗科技股份有限公司（以下 简称"公司"）董事会，就公司截至本意见出具日在任的独立董事 JIA HONG GAO、 王少飞、盛雷鸣的独立性情况进行评估并出具如下专项意见： 上海联影医疗科技 ...

关于上海联影医疗科技股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：上海联影医疗科技股份有限公司 审计单位：安永华明会计师事务所（特殊普通合伙） 联系电话：+86 10 5815 3000 Ernst & Young Hua Ming LLP Level 17, Ernst & Young Tower Orlental Plaza, I East Chang An Avenue Dongcheng District Beljing, China 100738 安永华朝会计师事务所(特殊营通合伙) 中国北京市东城区东长安街1号 东方广场安永大楼 17 层 邮政编码: 100738 Tel 电话:+86 10 5815 3000 Fax 传赢:+B6 10 8518 8298 ey.com 非经营性资金占用及其他关联资金往来情况的专项说明 上海联影医疗科技股份有限公司董事会: 我们审计了上海联影医疗科技股份有限公司的2024年度财务报表,包括2024年12 月31日的合并及公司资产负债表,2024年度的合并及公司利润表、股东权益变动表和 ...

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology sector [4]. Core Viewpoints - The domestic weight loss drug market is entering commercialization, emphasizing the importance of sales capabilities for companies [1][19]. - The competition in the global weight loss drug market is intensifying, particularly between Novo Nordisk and Eli Lilly, where marketing strategies play a crucial role in sales performance [19][23]. - Companies with advanced R&D progress and strong sales execution will hold competitive advantages in the commercialization phase of weight loss drugs [1][19]. Summary by Sections Market Review - The pharmaceutical and biotechnology index rose by 1.16%, outperforming the CSI 300 index by 0.77 percentage points but underperforming the ChiNext index by 1.08 percentage points, ranking 15th among 31 sub-industries [1][15]. - The Hong Kong Hang Seng Healthcare Index increased by 8.44%, outperforming the Hang Seng Index by 6.12 percentage points [1][15]. Company Updates - Recent clinical application updates include Baiyi Shenzhou's injection BGB-B2033 and Nuo Cheng Jian Hua's injection ICP-B794, both newly undertaken [27]. - Ongoing clinical trials include Bo Rui Pharmaceutical's BGM0504 and Hua Dong Pharmaceutical's HDM1002, currently in Phase III [27]. Investment Strategy - The report suggests a structural selection of investment opportunities based on payment willingness and ability, focusing on three payment channels: in-hospital payments, out-of-pocket payments, and overseas payments [2]. - Key recommended companies include Heng Rui Pharmaceutical, Mai Rui Medical, and United Imaging Healthcare [2]. Company Profit Forecasts and Valuation - Heng Rui Pharmaceutical is rated "Accumulate" with a projected EPS of 0.99 yuan for 2024 and a PE ratio of 51 [3]. - Mai Rui Medical is rated "Buy" with a projected EPS of 11.47 yuan for 2024 and a PE ratio of 19 [3]. - United Imaging Healthcare is also rated "Buy" with a projected EPS of 2.88 yuan for 2024 and a PE ratio of 44 [3].

华为与中山七院共建"鲲鹏+昇腾"自主创新平台，将实现医院业务系统、数据库及ICT基础设施的智能 化。创新中心通过AI驱动影像质控优化、远程智能诊疗探索、智慧化病区管理升级及AI辅助临床决策 优化，打造覆盖诊疗全流程的智能化解决方案。 中山七院院长何裕隆强调，智慧医院是公立医院高质量发展的必由之路，此次合作是院企技术整合的典 范，期待通过共建创新中心，实现"优质资源全域共享"。 深圳商报•读创客户端记者 陈姝 4月23日，中山大学附属第七医院（以下简称"中山七院"）与华为技术有限公司（下文简称"华为"）签 署全面合作协议，并与联影医疗技术集团有限公司、深圳市联新移动医疗科技有限公司（以下简称"联 影""联新"）在深圳共同签署三方合作协议，合作共建"中山大学附属第七医院智慧医疗联合创新中 心"（以下简称"创新中心"）。 揭牌仪式（活动主办方供图） 创新中心将采用即将建成的10.0P级医疗人工智能算力中心，通过产学研医深度融合，推动智慧医疗自 主创新，促进医院高质量发展，助力国家实施"健康中国"战略。 在揭牌仪式上，中山七院副院长魏富鑫表示，此次的合作亮点是通过技术赋能，破解临床痛点。此次合 作以打造"三位一体"智 ...